Clinical Trial Update: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ORIN1001 in patients with advanced solid tumor and relapsed/refractory metastatic breast cancer has completed the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumor

Drugs mentioned

• ORIN1001

Snippet

Sponsor: Orinove, Inc. | Conditions: Advanced Solid Tumor, Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED